Business, energy, technology, markets and global industry news from Business News Today

Helicon peptides

PharmaDeviceNews Helicon peptides
Representative image of oncology drug discovery as Parabilis Medicines’ IPO surge puts Helicon peptides, zolucatetide, desmoid tumors, and Wnt-driven cancer treatment under sharper focus.
Pharma & Biotech

Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution

Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.

Read More
Pharma & Biotech

Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates

ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.

Read More